FDA Approves New Medication for Agitation in Alzheimer's Dementia
Otsuka and Lundbeck secured a crucial FDA approval for brexpiprazole (Rexulti) to treat agitation associated with Alzheimer's dementia, a symptom affecting nearly half of all patients that has long lacked targeted therapies (https://jamanetwork.com/journals/jama/fullarticle/2849527). This is the first FDA-approved treatment specifically for this indication. It opens a new and substantial commercial front beyond the drug's existing approvals.
Drug Profile
Drug Name: Brexpiprazole (Rexulti)
Mechanism of Action: Brexpiprazole is a serotonin-dopamine activity modulator (SDAM). Its efficacy is believed to be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. This profile allows it to modulate, rather than simply block, key neurotransmitter pathways implicated in psychosis and mood.
Drug Class: Atypical Antipsychotic
Structural Distinction: Brexpiprazole is a structural analog of aripiprazole. It was designed to refine the pharmacodynamic profile, exhibiting lower intrinsic activity at the dopamine D2 receptor and higher affinity for the 5-HT1A and 5-HT2A receptors. This modification is theorized to maintain antipsychotic efficacy while potentially mitigating certain side effects associated with earlier-generation drugs, such as akathisia and restlessness.
Clinical Data
The approval was supported by two positive Phase 3 studies demonstrating a statistically superior reduction in the frequency of agitation symptoms versus placebo.
| Endpoint | Result | Comparator | Trial | | :--- | :--- | :--- | :--- | | Change in CMAI Total Score (Trial 1) | -22.6 | -17.3 (Placebo) | NCT01862640 | | Change in CMAI Total Score (Trial 2) | -22.0 | -15.4 (Placebo) | NCT01922258 | | Change in CGI-S Score (Trial 1) | -0.8 | -0.6 (Placebo) | NCT01862640 | | Change in CGI-S Score (Trial 2) | -0.9 | -0.6 (Placebo) | NCT01922258 |
*CMAI: Cohen-Mansfield Agitation Inventory; CGI-S: Clinical Global Impression–Severity of illness score. Both trials were 12 weeks in duration.*
Global Regulatory Status
Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.
| Regulatory Body | Status | Notes |
|---|---|---|
| Regulatory Body | Status | |
| FDA (United States) | ✓ Approved May 23, 2026 | |
| EMA (European Union) | No submission entry detected in BrunoSan DB for Alzheimer's agitation as of May 23, 2026. | |
| Health Canada | No submission entry detected in BrunoSan DB for Alzheimer's agitation as of May 23, 2026. | |
| ANVISA (Brazil) | No submission entry detected in BrunoSan DB for Alzheimer's agitation as of May 23, 2026. |
STATUS
Market Impact
The approval of Rexulti for Alzheimer's agitation carves out a new, well-defined market where treatment has historically relied on the off-label use of other antipsychotics, antidepressants, and benzodiazepines. These alternatives come with their own efficacy limitations and substantial side effect burdens. Rexulti’s primary competitive advantage is its on-label status, which will be a powerful tool for market access, physician